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Abstract
TTF-1 and Pax-8 are thyroid-specific transcription factors,
from homeo and paired box genes, respectively, that are
responsible for thyroid development and for thyroglobulin
and thyroperoxidase gene expression. However, TTF-1 and
Pax-8 preferentially bind to the thyroglobulin and thyroper-
oxidase promoters, respectively. Here, we have studied a
patient with defective thyroglobulin synthesis. Thyroglobu-
lin mRNA was found at very low levels while the mRNA
for thyroperoxidase was found to be more abundant com-
pared with control tissue. The low levels of thyroglobulin
mRNA are caused by a transcriptional defect due to the
virtual absence of TTF-1 expression as determined by
Northern blot analysis, reverse transcriptase-PCR, and
electrophoretic mobility shift assays. The level of Pax-8
mRNA was the same in the goiter and in the control thyroid.
These results are the first reported evidence of a congenital
goiter with a thyroglobulin synthesis defect due to the low
expression of the thyroid-specific transcription factor TTF-
1. Moreover, these data suggest that TTF-1 and Pax-8 would
be differentially regulating thyroglobulin and thyroperoxi-
dase gene transcription. (J. Clin. Invest. 1995. 96:781-785.)
Key words: congenital hypothyroidism * thyroglobulin de-
fect * thyroid transcription factors * thyroid-specific genes
* homeo and paired box genes
Introduction
Human congenital hypothyroidism is a clinical situation giving
rise to abnormal growth and neurological development which
is a consequence of low level production of thyroid hormones.
The biosynthesis of thyroid hormones requires the normal struc-
ture of the thyroglobulin (Tg).' Abnormalities in the synthesis
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1. Abbreviations used in this paper: EMSA, electrophoretic mobility
shift assay; RT, reverse transcription; Tg, thyroglobulin; TPO, thyroper-
oxidase; TSH, thyrotropin (thyroid stimulating hormone); TSH-R, TSH
receptor; TTF, thyroid transcription factor.
of Tg protein, changes in Tg mRNA and alterations in Tg gene,
have been described as the cause of human Tg synthesis defects
(1 ). Clinically, many of these patients exhibit very large goiter
as a consequence of chronically increased levels of thyrotropin
(TSH). Most of these abnormalities appear to be transmitted
in an autosomal recessive fashion with a high prevalence of
consanguinity in the affected families. Both sexes are affected
and the parents are considered heterozygous and unaffected.
Frequently more than one sibling is affected in one given gener-
ation.
The rat Tg promoter has been studied extensively (2) and
three thyroid-specific transcription factors have been identified
to bind to this promoter: thyroid transcription factors 1 and 2
('1TF-l and TTF-2) (2, 3) and Pax-8 (4). All of them bind to
the thyroperoxidase (TPO) promoter too (4, 5). However, TTF-
1 and Pax-8 preferentially bind to the Tg and TPO promoters,
respectively (4). In addition TTF-1 binds to the TSH receptor
(TSH-R) gene promoter (6, 7). The genes for T1TF-l and Pax-
8 have been cloned disclosing that they contain homeo (3)
and paired (8) boxes, respectively. It is accepted that both are
responsible for thyroid phenotype and development (9). The
recent availability of this information has given us the opportu-
nity to demonstrate here, for the first time, that the cause of a
congenital goiter in a woman with almost no detectable levels
of Tg mRNA was the low expression of the transcription factor
1TF-l1. Our data also show high levels of TPO mRNA and
normal levels of Pax-8. These results, taken together, suggest
that, though TTF-l and Pax-8 are able to bind to both Tg and
TPO promoters, each transcription factor must differentially
regulate each gene.
Methods
Case report. A woman with familial congenital goiter, with two brothers
affected, was studied. The clinical and biological reports suggested a
defective thyroglobulin synthesis. The family pedigree (Fig. 1) shows
no consanguinity or history of goiter. The genetic nature (autosomic
recessive) of the disease was ascertained by this finding and by the fact,
according to historical reports, that two brothers had the same clinical
abnormalities. Unfortunately they were not accessible for study. Infor-
mation about them was collected and we know that one of the brothers
was studied 20 yr ago and diagnosed as a Tg synthesis defect since he
presented the same clinical and laboratory data as the patient studied
here. He was operated on and a total thyroidectomy was performed.
The gland was studied in a different hospital and we could not recover
any piece of it. The other brother had goiter from childhood.
The study of the patient reported here commenced in 1967 when
she was 15 yr of age. No detailed medical record was available before
that year. Consultation at an endocrine clinic revealed the presence of
a large goiter and signs of tracheal compression. The patient showed
normal growth and mental development. The thyroid status parameters
corresponded with those described for familial congenital goiter and
were: a low serum T4 level, 2.1 jig/I00 ml (normal values 4-10 Agg/
100 ml); a low serum T3 level, 0.6 ng/ml (normal values 1-2 ng/ml);
and an elevated serum TSH level, 100 AU/ml (normal values 2-12
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r-,l /-X hFigure 1. Pedigree of the
family studied with con-
genital goiter. Squares
represent males and cir-
cles represent females.
The parents have been
considered heterozygous
and unaffected. The
arrow indicates the pa-
tient studied in this work.
Two brothers are also af-
fected.
kLU/ml). The '27I content and the protein bound iodine were low, 2.8
and 1.6 jug/ml, respectively. Thyroidal radio iodine uptake (131I) was
elevated at 2 h (78%) and 24 h (94%). The perchlorate discharge
test was negative. Serum Tg level was undetectable. At this point a
hemithyroidectomy was performed, after treatment of the patient with
thyroid extract. After several follow-up visits, in 1980 the patient again
exhibited a high TSH level (80.7 pg/ml) and a low T3 level (0.3 ng/
ml). The patient received further thyroid extract treatment and in 1989
it was decided that a total thyroidectomy was necessary. The control
thyroid was obtained from the normal tissue of three different human
adenomas. All the pieces from the different glands were stored at -70'C
for both biochemical and molecular studies.
Gel filtration and electrophoresis. Thyroid tissue (controls and dif-
ferent parts of the goiter) was sliced and homogenized in buffer A
(10 mM Tris-HCl, pH 7.7, containing 150 mM NaCl). Subcellular
fractionation was performed using sequential centrifugation. The
100,000 g supernatant was fractionated on a Sepharose 6B column using
buffer A as eluent. The fractions corresponding to each peak were
pooled and concentrated for subsequent SDS-PAGE (7%).
Iodine and iodoamino acids determination. Total 127I content was
measured in the homogenate, in the S100 fraction, and in the different
column peaks (10). The 19 S Tg peak was digested with pronase
to determine iodothyronines and iodotyrosines after chromatographic
analysis (11).
RNA isolation and Northern blot analysis. Total RNA was extracted
by the guanidinium-isothiocyanate method (12). In some cases
poly(A)+ RNA was obtained by oligo (dT)-cellulose chromatography
(13). Samples of total RNA or poly(A)+ RNA were electrophoresed
in 1% agarose gels containing 2.2 M formaldehyde, blotted to nylon
membranes (Nytran; Schleicher and Schuell, Keene, NH), and hybrid-
ized with different probes labeled by random oligo priming (13). We
have previously isolated a partial human TTF-1 cDNA ( 1,200 bp, corre-
sponding to the 3' end of the rat c-DNA [3]) from a human thyroid
cDNA X-gtl 1 expression library.
The Northern blots were densitometrically scanned. The data are
represented as the mean±the standard deviation of three independent
experiments performed with RNA from different parts of the goiter or
the three different control glands.
Reverse transcription and polymerase chain reaction (RT-PCR).
The reverse transcription reaction was performed from 5 fg of total
RNA in 20 il of reaction mixture containing 2 jiL of 10 X PCR buffer
(Perkin-Elmer Cetus Corp., Norwalk, CT), 40 U RNasin (Promega,
Madison, WI), 400 U Moloney murine leukemia virus reverse tran-
scriptase (GIBCO-BRL, Gaithersburg, MD), 400 AM deoxynucleotides
(dNTPs) (Pharmacia Biotech Inc., Piscataway, NJ), and 1 yg/sample
of 6-mer oligonucleotide [d(N6)5 '-P04] (Pharmacia Biotech Inc.). In-
cubations were performed for 30 min at 420C, 5 min at 950C, and 5
min at 50C. After cooling, half of the volume of the RT reaction was
adjusted to 80 ,l and 2.5 U of Taq polymerase (Perkin-Elmer Cetus
Corp.), 8 Ml of lOX PCR buffer, and 2 AM of the appropriate primer
was added. The TTF-I primers were TI (CGCTGTCCTGCTGCAGTh-
ACTGCTGCGCCGCC) and T2 (GCCGGAAGCGTCGGGTGCTCT-
TCTCCCAG). The ,l3-actin primerswe e-- 1 (GTGTAAAACGCA-
GCTCAGTAACAGTCCG) and /32 (GGTATGGAATCCTGTGGC-
ATCCATGAAA). The PCR reaction was run on a DNA thermal cycler
(Perkin-Elmer Cetus Corp.) with the following conditions: denaturation
at 950C for 30 s, annealing at 60'C for 30 s, and extension at 720C for
1 min. For TTF-I and f3-actin 40 and 35 cycles were used, respectively.
The PCR products were electrophoresed in a 2% agarose gel, blotted
onto nylon membranes, and hybridized with human TTF-1 and rat /3-
actin probes.
Nuclear extract preparation and mobility shift assays. Nuclear ex-
tracts were performed as described previously (2). Protein concentration
was measured with a protein assay kit (Bio Rad Laboratories, Hercules,
CA) using bovine serum albumin as the standard. For electrophoretic
mobility shift assays (EMSA), 5 Mg of nuclear proteins was incubated
with 50 pg of 32P-labeled double-stranded DNA oligonucleotide C (5'-
CACTGCCCAGTCAAGTGTTCTTGA-3') or A (5'-TACTGATTA-
CTCAAGTATTCTTAG-3') as described (2). The resulting DNA-pro-
tein complexes were separated from free DNA on a 5% polyacrylamide
gel (2).
Results
Biochemical and molecular analysis defining the patient as a
thyroglobulin synthesis defect. Gel filtration and SDS-PAGE
revealed that almost no thyroidal Tg is present in the patient
(Fig. 2, a and b). It is important to note the conspicuous albumin
peak present in the goiter that is iodinated (0.74 jig 1271 /mg
protein). The fractions corresponding to the 19S Tg of the
goiter were digested with pronase and afterwards subjected to
iodoamino acid analysis. Neither iodothyronines nor iodotyro-
sines were detected. The results reported above suggest a defect
in Tg gene expression. To confirm this we measured Tg mRNA
levels by Northern blotting of total RNA from control thyroid
or goiter after hybridization with a human Tg cDNA probe
(14). As shown in Fig. 2 c, the size of the Tg mRNA was
normal (8.4 kb) in both cases. However, very low levels of Tg
mRNA were observed in the goiter. After quantification of the
autoradiograms by densitometric scanning and correction using
the levels of f3-actin mRNA (15) (Fig. 2 d) we observed that
the levels of Tg mRNA in the goiter were 20-fold less abundant
compared with the control.
We also analyzed the levels of TPO mRNA by hybridization
of Northern blots with the human TPO cDNA (16), since it
has been previously described that high levels of TPO mRNA
are present in this kind of familial congenital goiter ( 1). The
results indicate that the levels of TPO mRNA in the goiter are
very high (10-fold over the control) (Fig. 2, c and d).
77fF-i and Pax-8 gene expression. Since TTF-1 is the main
factor regulating Tg transcription, we hypothesized that the low
levels of Tg mRNA in the goiter could be due to the low
expression of TTF-1 mRNA. We first cloned a partial sequence
( 1.2 kb from the 3 '-end) of TTF-I cDNA from a human thyroid
expression library. The human clone obtained (hTTF-1 ) showed
high homology with the corresponding rat clone and was subse-
quently used as a probe. Northern blots containing poly(A)+
RNA from the goiter and from the control thyroid were hybrid-
ized with the hTTF- 1 probe (Fig. 3 a, left). The results obtained
indicated the virtual absence of TTF-1 mRNA from the goiter
(Fig. 3 a, lanes 1 and 2). The 2.4-kb TTF-1 transcript in the
normal human thyroid tissue is shown in Fig. 3 a, lanes 3-5.
Nevertheless, the high levels of TPO mRNA detected were
contradictory with our hypothesis as TTF-1 also binds to the
TPO promoter (5). Another transcription factor, Pax-8, has
been identified. It is known to bind to the TPO promoter with
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Figure 2. (a) Gel chromatography pattern of the
soluble protein fraction from the congenital goi-
ter (dashed line) and the control tissue (continu-
ous line). Absorbance at 280 nm was monitored
in each fraction. The elution positions of 27S
Tg, 19S Tg, and albumin are indicated above
each peak. The normal 19S Tg peak is absent in
the goiter. However, the levels of albumin are
greater compared with the control. (b) The mate-
rial present in the peak corresponding to 19S Tg
was concentrated and subjected to electrophore-
sis in SDS-PAGE (7%). Tg standard and mark-
ers were run in another lane (not shown). No
Tg protein is detected in the goiter (G) after
staining of the gel. (c) Representative Northern
blots with 30 ug of total RNA from the goiter
and the control glands hybridized with the corre-
sponding hTg (top), hTPO (middle), and rf3-
actin (bottom) probes. (d) Results obtained after
autoradiography and scanning densitometry of
the Northern blots. In each case the mRNA levels
for Tg and TPO (shaded and hatched bars, re-
spectively) were corrected to those obtained for
f3-actin. The signal obtained from the control
thyroid was normalized to 100. The results are
the mean±SD of three independent experiments
performed with RNA from different parts of the
goiter or the three different control glands.
a higher affinity than to the Tg promoter and overlaps one of
the TiTF-i binding sites (4). Therefore the expression of this
factor was determined in the goiter. Since human Pax-8 has
been cloned (17) and shows a very high homology with that
of rat, Northern blots containing total RNA from the goiter and
the control thyroid were hybridized with the rat Pax-8 probe
(4). The results obtained showed normal levels of the 3.1-kb
Pax-8 mRNA in both goiter and control thyroid (Fig. 3 a, right).
Very low levels of TTFF-i were detected by RT-PCR. Total
RNA from the goiter and from the control thyroid was reverse
transcribed and the corresponding DNA obtained was amplified
with specific primers for TITF-I and ,B-actin. Fig. 3 b, left,
shows low levels of amplified 171FF-i in the goiter compared
with the control thyroid. The levels of amplified 3-actin were
the same in both cases. Southern blotting and hybridization with
the hTTF-1 and ,B-actin probes demonstrated the specificity of
the amplified products (Fig. 3 b, middle and right). Although
this is not a quantitative RT-PCR, the fact that we have used
the same amount of total RNA (from goiter and control) and
amplified two genes at the same time suggests that the levels
of 1T1FF-I mRNA in the goiter are - 20-fold lower compared
with the control.
Analysis of the ITF-1/DNA complexformation. By EMSA
we have studied the TT1FF-I protein in the goiter and its capacity
to bind to its corresponding site within the Tg promoter. Nuclear
extracts from normal human thyroid or from the goiter were
a Figure 3. TTF-I and Pax-8 geneTTF-1 Pax8 expression. (a) 5 or 20 jig of
poly(A)+ RNA from the goiter
2.4Kb -...-mRNA *3.1 Kb(laneslIand 2)or 2.5 or 5 gof
poly(A)+ RNA from the controls
1 2 3 4 5 6 7 . (lanes 3-5) was hybridized with
G C G C the 3'- end human cDNA probe
for TTF-1. 30 I.g of total RNA
from the goiter (lane 6) and from
b the control thyroid (lane 7) washybridized with the full-length
C G C G C G probe for rat Pax-8 (10). Two rep-
480bp- s >; <;,- ~7-A0>t _ resentative Northern blots are
shown. (b) Analysis of TTF-I
gene expression by RT-PCR. To-
260bA* tal RNA from the goiter and thebp~w>--io.TTF-ITT control thyroid were reverse tran-
scribed and then amplified with
specific primers from TIF-1 and
,B-actin cDNAs. PCR products were run on 2% agarose gel and stained with ethidium bromide (left). The sizes of the amplified products are
indicated. After Southern blotting, the PCR products were hybridized with h-TTF-l probe (middle) or with a rat /3-actin probe (right).
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Figure 4. EMSA with nuclear extracts from the control and the goiter
tissues incubated with the 32P-labeled C or A oligonucleotides corre-
sponding to two different regions of the Tg promoter where the thyroid-
specific transcription factor TTF-l binds. An ubiquitous protein (UFA)
also binds to the A region. No TTF-l /DNA complex is observed using
nuclear extracts obtained from the goiter when C or A oligos were used
(lanes 3 and 7). TTF- I/DNA complex is detected in the control gland
(lanes 1 and 5). As shown in lane 7, although there is not a TTF-l/
DNA complex in the goiter, the presence of the UFA/DNA complex
is as clear as in the control (lane 5). All the complexes are specific
since their bindings are competed with a 100-fold excess of cold oligo-
nucleotide C or A, respectively.
tested for the ability to bind to a 24-bp oligonucleotide C derived
from one of the TTF-1 binding sites within the Tg promoter
(2, 18). A retarded band was detected in the gel shift assay
when nuclear extracts from the control thyroid were used (Fig.
4, lane 1). The specificity of the complex was demonstrated
by competition experiments. The TT'F-1/DNA complex was
competed by a 100-fold excess of unlabeled oligonucleotide C
(Fig. 4, lane 2). However, no retarded band corresponding to
the TTF-1 /DNA complex was observed when nuclear extracts
prepared from the goiter were used (Fig. 4, lane 3). A protein/
DNA complex migrating below the TTF-1/DNA complex is
observed in goiter nuclear extracts, but the protein of this com-
plex is something different from TTF-' since it was not com-
peted by a 100-fold excess of unlabeled oligonucleotide C (Fig.
4, lane 4). A positive control in the EMSA was used to show
that the nuclear extracts from the goiter are capable of binding
to another DNA element. An oligonucleotide derived from the
A region of the Tg promoter was used (2, 18). TTF-1 and a
ubiquitous protein UFA bind to this region. As shown in Fig.
4, there are two retarded bands (TTF-1I/DNA and UFA/DNA
complexes) when nuclear extracts from control thyroid were
used (lane 5). However, only the UFA/DNA complex was
found in the goiter (Fig. 4, lane 7). The complexes are specific
since they were competed by an excess (100-fold) of unlabeled
oligonucleotide A (Fig. 4, lanes 6 and 8). These data confirm
that, even though we were able to detect very small levels of
TTF-1 mRNA by RT-PCR, this small amount is not sufficient
to be translated into the correspondingly active TTF-1 protein.
Discussion
The case presented in this study is in agreement with the estab-
lished diagnostic criteria for congenital goiter related to im-
paired Tg synthesis ( 1). The patient had an enormous quantity
of iodinated albumin and it has been suggested that iodoalbumin
could play a role replacing Tg in thyroid hormone formation
(19). In this case the low serum T3 and T4 levels found in the
patient suggested that even if the albumin is iodinated it is
not able to form enough thyroid hormone to prevent tissue
hypothyroidism.
Despite extensive studies, the molecular basis of most of
these defects remain unclear, however, it seems likely that many
different mutations in the Tg gene are responsible for Tg synthe-
sis defects (1). We have correlated the very low levels of 19S
Tg iodoprotein found in the goiter with the very low mRNA
levels of the 8.4-kb Tg transcript. An explanation of the patient's
condition within this study could be the presence of a mutation
in the Tg gene. Another possible alternative would be a Tg gene
promoter defect in TTF-1 and/or Pax-8 binding site. However,
we focused our efforts in a new direction. Until now there have
been no reports raising the possibility of a Tg gene transcription
defect. This hypothesis was established as a consequence of
two pieces of evidence: the almost undetectable level of Tg
mRNA and the recent cloning of two very important thyroid-
specific transcription factors TTF-1 and Pax-8 (3, 4). 1TF-1 is
the main regulator of Tg gene transcription. An important fea-
ture of this factor is that it is a homeoprotein. These kind of
proteins play a very important role in development, cell growth,
and differentiation processes (20). In the case of the rat, TTF-
1 has been defined as the thyroid phenotype determinant. Its
appearance in the rat embryo precedes Tg expression by 4-5
d (9). All together, this information suggested that the absence
or low expression of this factor could be the cause of congenital
goiters with Tg synthesis defect.
Nevertheless, the high levels of TPO mRNA detected were
contradictory with our hypothesis and the fact that TTF-1 also
binds to the TPO promoter (5, 21 ) is difficult to explain as the
TTF-1 levels were very low. Another factor, Pax-8, has been
recently identified. It is known to bind to the TPO promoter
with a higher affinity than to the Tg promoter, and overlaps one
of the sites for TTF-1 binding (4). Therefore, we decided to
study the expression of this factor in the goiter. The results
indicated normal levels of Pax-8 mRNA. At this point, the fact
is that both TTF-1 and Pax-8 are able to bind to the Tg and
TPO promoters in vitro. The situation in vivo could be different,
each gene being regulated in a different manner by each factor.
One possible explanation for the elevated levels of TPO mRNA
could be that, in normal tissue, TTF-1 is acting like a repressor
of TPO activation although it is activating Tg expression. The
fact that the same transcription factor is able to activate one
gene while repressing another has been described previously
(22). The mechanism of this repression would be by a competi-
tion between both an inactive form of T1F-1 and Pax-8 for the
same binding site in the TPO promoter. Therefore, because of
the absence of TTF-1 in the patient studied, no competition
would exist, thereby leading to the constitutive activation of
TPO by Pax-8.
TSH-R mRNA in the goiter was normal in size and as
abundant as the control (data not shown). Since there is not
reported evidence that Pax-8 binds to the TSH-R, we cannot
explain normal levels of TSH-R with the above explanation
for TPO. Our explanation is that although 1TF-1 binds and
transcribes the TSH-R promoter (7) other factors, different from
TTF-1, have been reported to control TSH-R gene expression
(23, 24). Such factors could regulate the TSH-R in this situa-
tion.
Very low levels of TTF-1 expression were detected by RT-
PCR, but not sufficient to be translated into the correspondingly
active TTF-1 protein, since in the EMSA we did not detect any
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1-FF-i /DNA complex. This suggested once more that Tl17F-1
is the main cause of this Tg synthesis defect. We cannot rule
out a possible mutation within the Tg promoter which would
alter Tg transcription, but the fact that 1-1F-1 is virtually absent
in the goiter should be considered enough to explain the defect.
The cause of the low 1FF-1 levels remains to be clarified. To
accomplish this goal it will be necessary to clone the entire
1TF-I human gene. The key feature of this work is that it is
the first report of a Tg synthesis defect due to the low levels
of a thyroid-specific transcription factor. To our knowledge few
other congenital defects considered to be caused by the absence
or altered expression of transcription factors have been reported
previously. It is known that the absence of a specific transcrip-
tion factor necessary for the transcription of the HLA class II
genes results in the absence of their protein products, which
is characteristic of one form of congenital severe combined
immunodeficiency disease (25). The causes of human congeni-
tal hypopituitarism have been reported as different mutations
in the gene of the pituitary-specific transcription factor Pit-l/
GHF-1. These mutations create either a stop codon or alter the
POU domain of such a factor, creating a protein unable to bind
to the pituitary genes that it regulates (26-28). These reports
confirm, in other tissues, that the lack or altered expression of
some transcription factors may lead to severe congenital defects.
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